

## DAFTAR ISI

|                                               |      |
|-----------------------------------------------|------|
| Halaman Sampul Depan.....                     | i    |
| Halaman Sampul Dalam .....                    | ii   |
| Prasyarat Gelar .....                         | iii  |
| Lembar Pengesahan .....                       | iv   |
| Halaman Penetapan Panitia Penguji Tesis ..... | v    |
| Halaman Pernyataan Orisinalitas.....          | vi   |
| Ucapan Terima Kasih .....                     | vii  |
| Ringkasan .....                               | x    |
| Summary .....                                 | xii  |
| Abstrak .....                                 | xiv  |
| Abstract .....                                | xv   |
| Daftar Isi.....                               | xvi  |
| Daftar Tabel.....                             | xix  |
| Daftar Gambar .....                           | xx   |
| Daftar Lampiran .....                         | xxi  |
| Daftar Singkatan dan Istilah .....            | xxii |

### BAB 1 PENDAHULUAN

|                              |   |
|------------------------------|---|
| 1.1 Latar Belakang.....      | 1 |
| 1.2 Rumusan Masalah .....    | 4 |
| 1.3 Tujuan.....              | 4 |
| 1.4 Manfaat Penelitian ..... | 5 |

### BAB 2 TINJAUAN PUSTAKA

|                                                             |    |
|-------------------------------------------------------------|----|
| 2.1 Kanker Payudara.....                                    | 6  |
| 2.1.1 Pengertian Kanker Payudara .....                      | 6  |
| 2.1.2 Etiologi dan Patogenesis Kanker payudara .....        | 7  |
| 2.1.3 Klasifikasi Kanker payudara .....                     | 8  |
| 2.1.4 Gejala klinis dab factor resiko kanker payudara ..... | 9  |
| 2.2 Karsinogenesis Kanker payudara.....                     | 12 |

|                                                                    |    |
|--------------------------------------------------------------------|----|
| 2.3 Respon Imun pada kanker payudara .....                         | 18 |
| 2.3.1 Peran Makrofag dalam respon imun .....                       | 18 |
| 2.3.2 Peran Interleukin 10 sel tumor pada TAMs.....                | 19 |
| 2.3.3 Peran <i>Tumor Necrosis Factor <math>\alpha</math></i> ..... | 21 |
| 2.3.4 Peran Interferon $\gamma$ sel tumor.....                     | 24 |
| 2.4 Tumbuhan <i>Cayratia Trifolia L</i> (Domin) .....              | 26 |
| 2.4.1 Taksinomi, Penggunaan tradisional dan Fitokimia.....         | 26 |
| 2.4.2 Kandungan kimia <i>Cayratia Trifolia L</i> (Domin) .....     | 28 |
| 2.4.3 Manfaat kandungan <i>Cayratia Trifolia L</i> (Domin) .....   | 28 |
| 2.5 Pemeriksaan Histologi.....                                     | 30 |
| 2.6 Pemeriksaan Imunohistokimia.....                               | 31 |

### BAB 3 KERANGKA KONSEP

|                               |    |
|-------------------------------|----|
| 3.1. Kerangka Konseptual..... | 36 |
| 3.2. Hipotesis.....           | 39 |

### BAB 4 METODOLOGI PENELITIAN

|                                                                                         |    |
|-----------------------------------------------------------------------------------------|----|
| 4.1. Jenis dan Rancangan Penelitian.....                                                | 40 |
| 4.2. Populasi, Besar Sampel dan Teknik Pengambilan Sampel .....                         | 41 |
| 4.2.1. Populasi dan besar sampel.....                                                   | 41 |
| 4.2.2. Teknik pengambilan sampel.....                                                   | 42 |
| 4.3. Variabel Penelitian dan Definisi Operasional .....                                 | 43 |
| 4.4. Alat dan Bahan Penelitian .....                                                    | 45 |
| 4.5. Lokasi dan Waktu Penelitian.....                                                   | 46 |
| 4.6. Prosedur Penelitian .....                                                          | 47 |
| 4.6.1. Pembuatan ekstrak <i>Cayratia Trifolia L</i> (Domin) dengan metode maserasi..... | 47 |
| 4.6.2. Persiapan karsinogen DMBA .....                                                  | 48 |
| 4.6.3. Pembuatan hewan coba model kanker payudara pada tikus putih ....                 | 49 |
| 4.6.4. Perlakuan pada hewan coba tikus putih .....                                      | 50 |
| 4.6.5. Pewarnaan dan pengamatan imunohistokimia .....                                   | 51 |
| 4.7. Kerangka Operaional Penelitian .....                                               | 53 |

|                         |    |
|-------------------------|----|
| 4.8. Analisis Data..... | 54 |
|-------------------------|----|

## BAB 5 HASIL DAN ANALISIS

|                                                                |    |
|----------------------------------------------------------------|----|
| 5.1 Pembuatan Model Hewan Kanker Payudara .....                | 55 |
| 5.2 Pemeriksaan Gambaran Histopatologi .....                   | 57 |
| 5.3 Pewarnaan Imunohistokimia .....                            | 58 |
| 5.3.1 Hasil Pewarnaan Ekspresi IL-10 .....                     | 58 |
| 5.3.2 Hasil Pewarnaan Ekspresi TNF- $\alpha$ .....             | 60 |
| 5.3.3 Hasil Pewarnaan Ekspresi IFN- $\gamma$ .....             | 63 |
| 5.4 Analisis Data.....                                         | 65 |
| 5.4.1 Uji Asumsi Data .....                                    | 65 |
| 5.4.2 Pengujian Berganda ( <i>Multiple Comparisons</i> ) ..... | 65 |

## BAB 6 PEMBAHASAN

|                                                     |    |
|-----------------------------------------------------|----|
| 6.1 Proses Pembentukan kanker pada tikus putih..... | 70 |
| 6.2 Ekstrak <i>Cayratia trifolia</i> .....          | 72 |
| 6.3 Ekspresi IL-10 pada tikus putih .....           | 74 |
| 6.4 Ekspresi TNF- $\alpha$ pada tikus putih .....   | 76 |
| 6.5 Ekspresi IFN- $\gamma$ pada tikus putih.....    | 78 |

## BAB 7 KESIMPULAN DAN SARAN

|                     |    |
|---------------------|----|
| 7.1 Kesimpulan..... | 79 |
| 7.2 Saran.....      | 79 |

|                      |    |
|----------------------|----|
| DAFTAR PUSTAKA ..... | 81 |
|----------------------|----|

## DAFTAR TABEL

|                                                                               |    |
|-------------------------------------------------------------------------------|----|
| Tabel 5.1 Ekspresi IL-10 pada tikus putih <i>Sprague Dawley</i> .....         | 59 |
| Tabel 5.2 Ekspresi TNF- $\alpha$ pada tikus putih <i>Sprague Dawley</i> ..... | 62 |
| Tabel 5.3 Ekspresi IFN- $\gamma$ pada tikus putih <i>Sprague Dawley</i> ..... | 64 |
| Tabel 5.4 Hasil Uji Berganda ( <i>Multiple Comparisons</i> ) .....            | 67 |

## DAFTAR GAMBAR

|                                                                                          |    |
|------------------------------------------------------------------------------------------|----|
| Gambar 2.1 Anatomi Payudara .....                                                        | 6  |
| Gambar 2.2 Patogenesis Kanker Payudara .....                                             | 8  |
| Gambar 2.3 Gambaran Umum Proses Karsinogenesis .....                                     | 14 |
| Gambar 2.4 Fase inisiasi, promosi dan progresi pada karsinogenesis .....                 | 18 |
| Gambar 2.5 <i>Induction of Anti-Tumor T Cell Response</i> .....                          | 20 |
| Gambar 2.6 NF- $\kappa$ B yang Memberi Sinyal Peradangan .....                           | 22 |
| Gambar 2.7 Persinyalan IFN- $\gamma$ .....                                               | 25 |
| Gambar 2.8 Tumbuhan Cayratia Trifolia L (Domin) .....                                    | 28 |
| Gambar 2.9 Daun Cayratia Trifolia L (Domin).....                                         | 28 |
| Gambar 2.10 Molekul dari kandungan Tanaman Cayratia Trifolia L (Domin) .                 | 29 |
| Gambar 2.11 <i>Blocking Endogenous Peroxidase</i> .....                                  | 34 |
| Gambar 3.1 Kerangka Konseptual.....                                                      | 37 |
| Gambar 4.1 Skema rancangan penelitian.....                                               | 41 |
| Gambar 4.2 Bagan Kerangka Operasional.....                                               | 55 |
| Gambar 5.1 Gambaran histologis payudara tikus.....                                       | 58 |
| Gambar 5.2 Ekspresi IL-10 pada jaringan <i>mammae</i> pada tikus normal (K0)....         | 59 |
| Gambar 5.3 Ekspresi IL-10 pada jaringan <i>mammae</i> pada tikus normal (K1)....         | 60 |
| Gambar 5.4 Mean jumlah ekspresi IL-10 pada masing-masing kelompok .....                  | 61 |
| Gambar 5.5 Foto miskrokopi ekspresi TNF- $\alpha$ pada jaringan <i>mammae</i> tikus .... | 62 |
| Gambar 5.6 Foto miskrokopi ekspresi TNF- $\alpha$ pada jaringan <i>mammae</i> tikus .... | 63 |
| Gambar 5.7 Mean jumlah ekspresi TNF- $\alpha$ masing-masing kelompok.....                | 64 |
| Gambar 5.8 Foto ekspresi IFN- $\gamma$ pada tikus normal dan induksi DMBA.....           | 65 |
| Gambar 5.9 Foto ekspresi IFN- $\gamma$ pada tikus perlakuan.....                         | 65 |
| Gambar 5.10 Mean jumlah ekspresi IFN- $\gamma$ masing-masing kelompok .....              | 66 |

## DAFTAR LAMPIRAN

|                                                     |     |
|-----------------------------------------------------|-----|
| Lampiran 1 Tata Cara Pemeliharaan Hewan Coba.....   | 87  |
| Lampiran 2 Perlakuan Terhadap Hewan Coba.....       | 90  |
| Lampiran 3 Tahap Pemrosesan Jaringan.....           | 92  |
| Lampiran 4 Prosedur Pewarnaan HE .....              | 93  |
| Lampiran 5 Prosedur Pewarnaan Imunohistokimia ..... | 94  |
| Lampiran 6 Hasil Analisis Data.....                 | 96  |
| Lampiran 7 Surat Keterangan Penelitian .....        | 104 |
| Lampiran 8 Dokumentasi Penelitian.....              | 105 |
| Lampiran 9 Data Sheet Antibody Monoclonal.....      | 112 |

## DAFTAR SINGKATAN

|        |                                                    |
|--------|----------------------------------------------------|
| ADCC   | : <i>Antibody Dependent Cellular Cytotoxicity</i>  |
| APC    | : <i>Antigen Presenting Cells</i>                  |
| AKT    | : Protein Kinase B                                 |
| ASI    | : Air Susu Ibu                                     |
| BCR-1  | : <i>Breakpoint Cluster Region Protein – 1</i>     |
| BCR-2  | : <i>Breakpoint Cluster Region Protein – 2</i>     |
| BRCA-1 | : Breast Cancer Gene - 1                           |
| BRCA-2 | : Breast Cancer Gene – 2                           |
| CD4    | : <i>Cluster of Differentiation 4</i>              |
| CD8    | : <i>Cluster of Differentiation 8</i>              |
| CD28   | : <i>Cluster of Differentiation 28</i>             |
| CD45   | : <i>Cluster of Differentiation 45</i>             |
| CMC.Na | : <i>Carboxymethyl Celulose Sodium</i>             |
| CTL    | : <i>Cytotoxic T - Lymphocyte</i>                  |
| CTLA-4 | : <i>Cytotoxic T Lymphocyte-Associated Protein</i> |
| DAB    | : <i>Diaminobenzidine tetrahydrochloride</i>       |
| DCIS   | : <i>Ductal carcinoma in situ</i>                  |
| DMBA   | : <i>7,12 Dimethylbenz(a) anthracene</i>           |
| DNA    | : <i>Deoxyribonucleic Acid</i>                     |
| EMT    | : <i>Epithelial to mesenchymal transition</i>      |
| ER     | : <i>Estrogen</i>                                  |
| ERK    | : <i>Extracellular signal regulating kinase</i>    |
| HER-2  | : <i>Human epidermal growth factor receptor-2</i>  |
| ICD    | : <i>International Classification of Disease</i>   |

|                |                                                            |
|----------------|------------------------------------------------------------|
| IDC-NOS        | : <i>Invasive ductal carcinoma not otherwise specified</i> |
| IFN- $\gamma$  | : <i>Interferron <math>\gamma</math> (gamma)</i>           |
| IHK            | : <i>Imunohistokimia</i>                                   |
| IL-1R          | : <i>Interleukin 1 R</i>                                   |
| IL-2           | : <i>Interleukin 2</i>                                     |
| IL-4           | : <i>Interleukin 4</i>                                     |
| IL-10          | : <i>Interleukin 10</i>                                    |
| IL-13          | : <i>Interleukin 13</i>                                    |
| iNOS           | : <i>Inducible Nitric Oxide Synthase</i>                   |
| IRAK1          | : <i>Interleukin-4 receptor-associated kinase</i>          |
| IRAK4          | : <i>Interleukin-1 receptor-associated kinase</i>          |
| M1/M2          | : <i>Makrofag 1/2</i>                                      |
| MBC            | : <i>Metaplastic breast cancer</i>                         |
| MDSC           | : <i>Myeloid-derived suppressor cell</i>                   |
| MAPK           | : <i>Mitogen-Activated Protein Kinase</i>                  |
| MyD88          | : <i>Myeloid differentiation primary response 88</i>       |
| NF- $\kappa$ B | : <i>Nuclear Factor kappa B</i>                            |
| NK             | : <i>Natural Killer Cells</i>                              |
| PD-1           | : <i>Cell Death protein</i>                                |
| PGE-2          | : <i>Prostaglandin E2</i>                                  |
| PI3K           | : <i>Phosphatidyl inositol-3 kinase</i>                    |
| PRR            | : <i>Pattern recognition receptor</i>                      |
| P53            | : <i>Protein 53</i>                                        |
| TAMs           | : <i>Tumor Associated Macrophages</i>                      |
| TGF- $\beta$   | : <i>Transforming Growth Factor - beta</i>                 |
| TH-2           | : <i>Helper T Cells</i>                                    |

TLR : *Toll Like Receptor*  
TNF- $\alpha$  : *Tumor Necrosis Factor - Alpha*  
WHO : *World Health Organization*